Background rate of low‐level HCV RNA in anti‐HCV confirmed‐positive and minipool nucleic acid test‐nonreactive blood donations. Issue 1 (9th December 2021)

• Record Type: Journal Article
• Authors: Groves, Jamel A.; Y. Dodd, Roger; Zhu, Xiaomei; Linnen, Jeffrey M.; Stramer, Susan L.
• Is Part Of: Transfusion. Volume 62:Issue 1(2022)
• Page Start: 143
• Page End: 150
• Publication Date: 2021-12-09
• Subjects: blood donors -- hepatitis C virus -- low‐level -- nucleic acid testing -- Ultrio Elite; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.16759
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: Background: In 2019, the Food and Drug Administration revised the requirement for further testing of anti‐HCV‐reactive donations testing nucleic acid (NAT)‐nonreactive via routine mini‐pool (MP)‐NAT. Individual donation (ID)‐HCV NAT was required as a supplemental test prior to a second FDA‐licensed anti‐HCV assay; if ID‐HCV‐NAT is reactive, no further testing is required. This study investigated the rate of low‐level RNA in anti‐HCV‐reactive donation samples prior to and following the implementation of supplemental ID‐HCV NAT. Study Design/Methods: A retrospective analysis was conducted on frozen plasma unit samples from 1161 anti‐HCV confirmed‐positive/HCV‐NAT‐nonreactive donations collected from December 2014 to January 2020. Samples were tested by multiple replicates on the Grifols Procleix Ultrio Elite (UE) assay and corresponding discriminatory HCV (dHCV) assay on the Procleix Panther System. Prospectively, the prevalence of low‐level RNA in 2912 anti‐HCV‐reactive donations detected through routine screening from April 2020 through March 2021 was determined. Results: In retrospective analyses, 10 (0.86%) of 1161 plasma samples were UE reactive, of which four (0.34%) were dHCV reactive (in all replicates of UE and dHCV). Of 2912 anti‐HCV‐reactive donation samples testing NAT‐nonreactive via routine MP‐NAT, three (0.1%; 95% CI: 0.04‐0.30) were dHCV reactive; 37% of the remaining samples were reactive by a second anti‐HCV assay and thus serologically confirmed. Conclusions: Retrospective and prospective analysis in comparison to earlier studies revealed that low‐level HCV‐RNA reactivity is decreasing over time. The very low HCV‐RNA rates may be due to the widespread use of highly effective, direct‐acting anti‐viral treatments for those diagnosed with HCV infection.